Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Are biosimilars similar enough?

Paul Cornes • 21 Mar 2017

Paul Cornes, MD from the University Hospital Bristol NHS Foundation Trust, Bristol, UK takes us through the concept of batch variation in branded biologics, how it has been justified by regulators and trusted by doctors, and how the same principles and strict rules have been put in place to justify the manufacture of biosimilar drugs.